BiotechTube

Durvalumab

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Solid Tumor

Conditions

Solid Tumor

Trial Timeline

Sep 5, 2019 → Oct 31, 2024

NCT ID
NCT04078152

About Durvalumab

Durvalumab is a approved stage product being developed by AstraZeneca for Solid Tumor. The current trial status is completed. This product is registered under clinical trial identifier NCT04078152. Target conditions include Solid Tumor.

What happened to similar drugs?

4 of 12 similar drugs in Solid Tumor were approved

Approved (4) Terminated (2) Active (8)
✅ARM A : IV iron + epoietin zeta + ARM B: IV iron + epoietin zeta sequence + ARM C : single epoietin zetaRocheApproved
✅denosumab + pamidronateAmgenApproved
✅Sacituzumab Govitecan-hiyGilead SciencesApproved
✅Binimetinib only treatment + Encorafenib only Treatment + Encorafenib & Binimetinib Treatment + Treatment of Encorafenib & Binimetinib & Ribociclib + Treatment of Encorafenib & Binimetinib & CetuximabPfizerApproved
🔄olanzapine plus fosaprepitant-based triple regimen + placebo plus fosaprepitant-based triple regimenSun PharmaceuticalPhase 3
🔄MEDI4736 (Durvalumab) + MEDI4736 (Durvalumab) + TremelimumabAstraZenecaPhase 3
🔄Pembrolizumab + Standard of Care (SOC) + Lenvatinib + Olaparib + MK-4280 + MK-4280AMerckPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (20)

NCT IDPhaseStatus
NCT06992609Phase 3Recruiting
NCT06826677Pre-clinicalCompleted
NCT05925530Phase 2Active
NCT04944173Phase 2Withdrawn
NCT05924880Phase 3Completed
NCT05617963Phase 2Recruiting
NCT05683977Pre-clinicalActive
NCT05303532Phase 3Recruiting
NCT05215106Phase 2Recruiting
NCT04416633ApprovedCompleted
NCT05933044Pre-clinicalCompleted
NCT04765709Phase 2Terminated
NCT04667312Pre-clinicalCompleted
NCT04062708Phase 2Active
NCT04230408Phase 2Completed
NCT04441138Phase 2Terminated
NCT05267392Phase 1/2UNKNOWN
NCT04543110Phase 2UNKNOWN
NCT04716946Phase 2Active
NCT04642469Phase 3Completed

Competing Products

20 competing products in Solid Tumor

See all competitors
ProductCompanyStageHype Score
ALG.APV-527Alligator Bioscience ABPhase 1/2
18
ATOR-1017Alligator Bioscience ABPhase 1
19
ATOR-1015Alligator Bioscience ABPhase 1
19
mRNA-4359ModernaPhase 2
0
mRNA-2752 + DurvalumabAstraZenecaPhase 1
29
mRNA-4106ModernaPhase 1
0
mRNA-4157 + Pembrolizumab + SoC TreatmentMerckPhase 1
33
mRNA-2416ModernaPhase 2
0
E7050EisaiPhase 1
29
AFM24 + Atezolizumab 840 MG in 14 ML InjectionAffimedPhase 1/2
14
EXS21546BiotrialPhase 1/2
14
SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent)Syros PharmaceuticalsPhase 1
11
BBP-398 + sotorasibBridgeBio PharmaPhase 1
18
BBP-398 (Formerly known as IACS-15509)BridgeBio PharmaPhase 1
18
SON-1010Sonnet BioTherapeuticsPhase 1
27
SON-1010Sonnet BioTherapeuticsPhase 1/2
18
RC220 + Doxorubicin (Adriamycin)Race OncologyPhase 1
30
BT1718Bicycle TherapeuticsPhase 1/2
22
NL-201 + Pembrolizumab Injection [Keytruda]NeurogenePhase 1
19
ZN-c3 + Carboplatin + Pegylated liposomal doxorubicin + Paclitaxel + Gemcitabine + BevacizumabZentalis PharmaceuticalsPhase 1
26